Research Article| Volume 17, ISSUE 4, P708-720, July 1995

Download started.


Efficacy and safety of mepyramine-theophylline-acetate in the treatment of asthmatic crisis in children

      This paper is only available as a PDF. To read, Please Download here.


      Mepyramine-theophylline-acetate (MTA), a theophylline derivative combined with an antihistamine, is used to treat patients with asthma. A double-blind, randomized, prospective, parallel-group study was conducted to evaluate the efficacy and safety of MTA in the treatment of asthmatic crisis in children 2 to 6 years of age. Forty patients with mild-to-moderate asthma were admitted to the study. The MTA group received 8 mg/kg per day of MTA by mouth in three divided doses for 7 days. The other group received 50 μL/kg per day of placebo in three divided doses for 7 days. Salbutamol (albuterol) syrup was used as the rescue drug if manifestations of asthma persisted. Both the MTA group and the placebo group had similar demographic characteristics at baseline. Both groups showed improvement of the asthma symptoms (cough, dyspnea, hypoventilation, and wheezing), as evaluated by the investigators at days 3 and 7. Patient diary scores showed earlier improvements in the MTA groups than in the placebo group. Both groups showed improvement in peak flow at days 3 and 7 (P = 0.005). The control group used more doses of salbutamol than the MTA group on days 2 through 6 and globally (mean ± SD, 6.79 ± 9.11 doses vs 1.29 ± 2.23 doses). The improvements in the placebo group were thought to be due to salbutamol. Three MTA patients dropped out of the trial, one because the parents felt that the treatment was not effective and two because of gastrointestinal manifestations (epigastric discomfort and vomiting). In the placebo group, two patients dropped out. One patient had epigastric discomfort and the other had to be treated in the emergency department for an exacerbation of the asthma. We conclude that MTA may be a good therapeutic option for the treatment of asthmatic crisis in children 2 to 6 years of age.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel SC
        • Rachelevsky GS
        Asthma in infants and children.
        J Allergy Clin Immunol. 1985; 76 (Part 1): 1-14
        • Croud B
        Special features of asthma in children.
        Chest. 1985; 85: 55-62
        • Sheffer Chairman AL
        Guideline for the diagnosis and management of asthma: National Heart, Lung and Blood Institute.
        J Allergy Clin Immunol. 1991; 88 (National Asthma Education Program expert panel report): 477-492
        • Tagtard A
        Delivery of prevention and care of asthmatic children.
        Lung. 1990; (Suppl): 256-262
        • Warner A
        • Abrahan WM
        • Phippis J
        New concepts of inflammation in asthma.
        Br J Clin Pract. 1989; S67: 2-5
        • Nsouli TM
        • Nsouli SM
        • Bellanti JA
        Neuro-immunoallergy inflammation: New pathogenic concept and future perspective of immediate and late reaction.
        Ann Allergy. 1988; 60 (Part 1): 379-389
        • Warner JO
        • Gotz M
        • Landau L
        • et al.
        Management of asthma consensus statement.
        Arch Dis Child. 1989; 64: 1065-1079
        • Wasserman S
        New light basic mechanism in asthma.
        J Res Dis. 1989; (Suppl): 521-526
        • Boner AL
        • Piacantine GL
        • Bellanti JA
        The need for early interventions in childhood asthma.
        Ann Allergy. 1993; 71: 85-86
        • Dukes MN
        • Holgate ST
        • Pauwels RA
        Report of an international workshop on risk and safety of asthma therapy.
        Clin Exp Allergy. 1994; 24: 160-165
        • Sears M
        • Toglor D
        • Print C
        • et al.
        Regular inhaled beta agonist treatment in bronchial asthma.
        Lancet. 1990; 336: 1391-1396
        • Spritzer W
        • Svissa S
        • Ernest P
        • et al.
        The use of beta agonists and the risk of death and near death from asthma.
        NEJM. 1992; 326: 501-506
        • Taylor DR
        • Sears MR
        • Herbison GP
        • et al.
        Regular inhaled beta agonist in asthma: Effect on exacerbation and lung function.
        Thorax. 1993; 48: 134-138
        • McFadden ER
        Therapy of acute asthma.
        J Allergy Clin Immunol. 1989; 84: 151-158
        • McFadden ER
        Methylxanthines in the treatment of asthma: The rise, the fall and the possible rise again.
        Ann Intern Med. 1991; 115: 323-324
        • Pauwels RA
        New aspects of the therapeutic potential of theophylline in asthma.
        J Allergy Clin Immunol. 1989; 83: 548-553
        • Ward AJ
        • Mc Kennif M
        • Evans JM
        • et al.
        Theophylline and its immunomodulatory role in asthma.
        Am Rev Respir Dis. 1993; 147: 518-523
        • Baker MD
        Theophylline toxicity in children.
        J Pediatr. 1986; 109: 538-543
        • Ellis E
        Theophylline toxicity.
        J Allergy Clin Immunol. 1985; 70: 297-301
        • Woocock AA
        • Johnson MA
        • Gedes DM
        Theophylline prescribing serum concentration and toxicity.
        Lancet. 1983; 2: 610-614
        • Múñoz F
        • Marti MA
        Treatment of asthma crisis in children with mepiramine-theophylline.
        Presented at the Tenth European Congress of Allergology and Clinical Immunology. 471977; (Prague, Czechoslovakia)
        • Llorens J
        • Busquets RM
        • García A
        Estudio de efecto broncodilatador de la Mepifilina en el asma infantil.
        Arch Pediat U Barcelona. 1991; 42: 161-166
        • Sienra-Monge JL
        • Prieto-Ursua L
        • Sol-Monterrey EG
        • et al.
        Valoración de la eficacia y seguridad de la mepifilina en solución oral en niños con crisis de asma de leve a moderada.
        Allergol Immunopathol. 1994; 22: 3-8